文献速递骨肌介入CTMR

骨样骨瘤经皮射频消融治疗后影像学表现的治疗相关改变

Treatment-related alterations of imaging findings in osteoid osteoma after percutaneous radiofrequency ablation.
PubMed 文献 · Skeletal Radiol · 2019-03-06

本研究纳入30例接受CT引导射频消融的骨样骨瘤患者,随访CT和动态增强MRI显示,随访期瘤巢尺寸较治疗前显著缩小(p=0.002),所有患者SImax和SIT曲线斜率均下降,SIT曲线斜率与Tmax对长期预后有重要阳性预测价值,治疗后3个月内单次动态增强MRI对无症状患者可能足够。

要点

  • 射频消融治疗骨样骨瘤临床成功率达100%,随访影像可见瘤巢缩小、SImax及SIT曲线斜率下降。
  • SIT曲线斜率在治疗前与第一、第二随访期之间均显著下降,Tmax对长期预后有重要阳性预测价值。
  • 治疗后3个月内单次动态增强MRI对无症状患者可能足以评估疗效。

核心结论

  • 射频消融是骨样骨瘤有效且安全的治疗选择,随访影像中SIT曲线斜率和Tmax对长期预后有最重要阳性预测价值,治疗后3个月内单次动态增强MRI对无症状患者可能足够。

研究设计与样本

  • 纳入30例(女7例、男23例)接受CT引导射频消融的骨样骨瘤患者,随访影像分为第一(1-3个月)和第二(>6个月)两组,比较CT和动态增强MRI表现。

关键影像表现/征象

  • 治疗前骨样骨瘤瘤巢平均大小为5.85±1.98 mm。
  • 所有患者(100%)随访MRI显示SImax和SIT曲线斜率下降。
  • SImax在治疗前与第二随访期之间显著下降,SIT曲线斜率在治疗前与两个随访期之间均显著下降。

诊断标准与关键数值

  • 临床成功率为100%。
  • 瘤巢尺寸在治疗前与第二随访期之间差异有统计学意义(p=0.002)。

临床应用与阅片要点

  • 随访影像中可关注SIT曲线斜率和Tmax,二者对长期预后有最重要阳性预测价值。
  • 对无症状患者,治疗后3个月内单次动态增强MRI可能足以评估疗效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We aimed to report the long-term outcomes of osteoid osteoma patients and to determine CT and dynamic contrast-enhanced MR imaging characteristics of radiofrequency ablation (RFA) treatment related changes of osteoid osteoma between follow-up periods.

MATERIALS AND METHODS: Thirty patients (seven female, 23 male) who underwent CT-guided RFA of osteoid osteoma were included. Follow-up imaging examinations were divided into two subgroups; first (1-3 months) and second (> 6 months) periods. Nidus size, calcification, cortical thickening, maximum signal intensity (SImax), time of SImax (Tmax), slope of signal intensity-time (SIT) curves were noted. CT and dynamic MR imaging findings were compared between follow-up periods.

RESULTS: Clinical success rate was 100%. The mean of OO nidi size was 5.85 ± 1.98 mm before treatment. There was a significant difference for OO nidi sizes between pretreatment and second follow-up period examinations (p = 0.002). SImax and slope of SIT curves of all patients (100%) showed decrease on follow-up MRIs. There was a significant decrease for SImax values between pretreatment and second follow-up period. There was a significant decrease for slope of SIT curves between pretreatment and both follow-up periods.

CONCLUSIONS: RFA is an effective and safe treatment choice for osteoid osteomas. On follow-up imaging, slope of SIT curve and Tmax have the most important positive predictive value for long-term outcomes and single dynamic contrast-enhanced MRI within first 3 months after treatment may be sufficient for symptom-free patients.

来源:Skeletal Radiol,查看原文。版权归原作者所有。

引用

  1. Erbaş G, Şendur HN, Kiliç HK, et al. Treatment-related alterations of imaging findings in osteoid osteoma after percutaneous radiofrequency ablation. Skeletal Radiol. 2019. PMID: 30840098. doi:10.1007/s00256-019-03185-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。